EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
[Brackets] indicate matter deleted from existing law.
*sb0189*
SENATE BILL 189
J3 2lr0055
(PRE–FILED)
By: Chair, Judicial Proceedings Committee (By Request – Departmental – Health)
Requested: October 5, 2021
Introduced and read first time: January 12, 2022
Assigned to: Judicial Proceedings
A BILL ENTITLED
AN ACT concerning 1
Controlled Substances – Schedules 2
FOR the purpose of altering the lists of substances designated as controlled dangerous 3
substances under certain schedules under the Maryland Controlled Dangerous 4
Substances Act; and generally relating to schedules for controlled dangerous 5
substances. 6
BY repealing and reenacting, with amendments, 7
Article – Criminal Law 8
Section 5–402 through 5–406 9
Annotated Code of Maryland 10
(2021 Replacement Volume and 2021 Supplement) 11
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 12
That the Laws of Maryland read as follows: 13
Article – Criminal Law 14
5–402. 15
(a) Schedule I consists of each controlled dangerous substance: 16
(1) listed in this section; 17
(2) added to Schedule I by the Department under § 5–202(b) of this title; or 18
(3) designated as a Schedule I controlled dangerous substance by the 19
federal government unless the Department objects under § 5–202(f) of this title. 20
(b) Unless specifically excepted under this subtitle or listed in another schedule, 21 2 SENATE BILL 189
any of the following opiates, including their isomers, including optical and geometric 1
isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the 2
existence of such isomers, esters, ethers, or salts is possible within the specific chemical 3
designation, are substances listed in Schedule I: 4
(1) acetyl–alpha–methylfentanyl (N–[1–(1–methyl–2–phenethyl)–4–5
piperidinyl]–N–phenylacetamide); 6
(2) acetylmethadol; 7
(3) acetyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacetamide); 8
(4) Acryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacrylamide; 9
(5) AH–7921 (3,4–dichloro–N–[(1–dimethylamino) cyclohexylmethyl]) 10
benzamide; 11
(6) allylprodine; 12
(7) alphacetylmethadol, except levo–alphacetylmethadol; 13
(8) alphameprodine; 14
(9) alphamethadol; 15
(10) alpha–methylfentanyl (N –[1–(alpha–methyl–beta–phenyl)ethyl 16
–4– piperidyl] propionanilide; 1–(1–methyl–2–phenylethyl)–4–(N–propanilido) piperidine); 17
(11) alpha–methylthiofentanyl (N –[1–methyl–2–(2–thienyl)ethyl 18
–4– piperidinyl]–N–phenylpropanamide); 19
(12) benzethidine; 20
(13) betacetylmethadol; 21
(14) beta–hydroxyfentanyl (N –[1–(2–hydroxy–2–phenethyl) 22
–4–piperidinyl]–N–phenylpropanamide); 23
(15) beta–hydroxy–3–methylfentanyl (N–[1–(2–HYDROXY–2–24
PHENYLETHYL )–3–METHYL–4–PIPERIDINYL]–N–PHENYLPROPANAMIDE ; 25
(16) BETA–HYDROXYTHIOFENTANYL (N–[1–[2–hydroxy–2–(thiophen–2–26
yl)ethyl]piperidin–4–yl]–N–phenylpropionamide); 27
(17) betameprodine; 28
(18) betamethadol; 29 SENATE BILL 189 3
(19) BETA–METHYLFENTANYL (N–PHENYL–N–(1–(2 1
–PHENYLPROPYL )PIPERIDIN–4–YL)PROPIONAMIDE ; ALSO KNOWN AS Β –2
METHYLFENTANYL ); 3
(20) BETA′–PHENYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 4
–N,3–DIPHENYLPROPANAMIDE ; ALSO KNOWN AS Β ′–PHENYL FENTANYL ; 5
3–PHENYLPROPANOYL FENT ANYL); 6
[(19)] (21) betaprodine; 7
[(20)] (22) butyryl fentanyl (N –(1–phenethylpiperidin–4–yl) 8
–N–phenylbutyramide); 9
[(21)] (23) clonitazene; 10
(24) CROTONYL FENTANYL ((E)–N–(1–PHENETHYLPIPERIDIN –4–YL) 11
–N–PHENYLBUT –2–ENAMIDE); 12
(25) CYCLOPENTYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 13
–N–PHENYLCYCLOPENTANECA RBOXAMIDE); 14
(26) CYCLOPROPYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 15
–N–PHENYLCYCLOPROPANECA RBOXAMIDE); 16
[(22)] (27) dextromoramide; 17
[(23)] (28) diampromide; 18
[(24)] (29) diethylthiambutene; 19
[(25)] (30) difenoxin; 20
[(26)] (31) dimenoxadol; 21
[(27)] (32) dimepheptanol; 22
[(28)] (33) dimethylthiambutene; 23
[(29)] (34) dioxaphetyl butyrate; 24
[(30)] (35) dipipanone; 25
[(31)] (36) ethylmethylthiambutene; 26
4 SENATE BILL 189
[(32)] (37) etonitazene; 1
[(33)] (38) etoxeridine; 2
(39) FENTANYL CARBAMATE (ETHYL (1–PHENETHYLPIPERIDIN 3
–4–YL)(PHENYL)CARBAMATE ); 4
[(34)] (40) 4–Fluoroisobutyryl fentanyl (N –(4–fluorophenyl)–N–(1 5
– phenethylpiperidin–4–yl)isobutyramide; 6
(41) 2′–FLUORO ORTHO –FLUOROFENTANYL (N–(1–(2 7
–FLUOROPHENETHYL )PIPERIDIN–4–YL)–N–(2–FLUOROPHENYL )PROPIONAMIDE ; 8
ALSO KNOWN AS 2′–FLUORO 2–FLUOROFENTANYL ); 9
[(35)] (42) furanyl fentanyl (N –(1–phenethylpiperidin–4–yl)–N 10
–phenylfuran–2–carboxamide); 11
[(36)] (43) furethidine; 12
[(37)] (44) hydroxypethidine; 13
(45) ISOBUTYRYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 14
–N–PHENYLISOBUTYRAMIDE ); 15
[(38)] (46) ketobemidone; 16
[(39)] (47) levomoramide; 17
[(40)] (48) levophenacylmorphan; 18
(49) METHOXYACETYL FENTAN YL (2–METHOXY–N–(1 19
–PHENETHYLPIPERIDIN –4–YL)–N–PHENYLACETAMIDE ); 20
(50) 4′–METHYL ACETYL FENTAN YL (N–(1–(4 21
–METHYLPHENETHYL )PIPERIDIN–4–YL)–N–PHENYLACETAMIDE ); 22
[(41)] (51) 3–methylfentanyl (N –[3–methyl–1–(2–phenylethyl) 23
–4–piperidyl]–N–phenylpropanamide); 24
[(42)] (52) 3–methylthiofentanyl (N–[3 25
–METHYL–1–(2–THIENYLETHYL )–4–PIPERIDINYL]–N–PHENYLPROPANAMIDE ); 26
[(43)] (53) morpheridine; 27
[(44)] (54) MPPP (1–methyl–4–phenyl–4–propionoxypiperidine); 28 SENATE BILL 189 5
[(45)] (55) mt–45 (1–cyclohexyl–4–(1,2–diphenylethyl)piperazine); 1
[(46)] (56) noracymethadol; 2
[(47)] (57) norlevorphanol; 3
[(48)] (58) normethadone; 4
[(49)] (59) norpipanone; 5
[(50)] (60) ocfentanil (N –(2–fluorophenyl)–2–methoxy–N–(1 6
– phenethylpiperidin–4–yl)acetamide); 7
(61) ORTHO–FLUOROACRYL FENTANYL (N–(2–FLUOROPHENYL )–N 8
–(1–PHENETHYLPIPERIDIN –4–YL)ACRYLAMIDE ); 9
(62) ORTHO–FLUOROBUTYRYL FENTAN YL (N–(2–FLUOROPHENYL )–10
N–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ; ALSO KNOWN AS 2 11
–FLUOROBUTYRYL FENTAN YL); 12
(63) ORTHO–FLUOROFENTANYL (N–(2–FLUOROPHENYL )–N 13
–(1–PHENETHYLPIPERIDIN –4–YL)PROPIONAMIDE ); ALSO KNOWN AS 2 14
–FLUOROFENTANYL); 15
(64) ORTHO–FLUOROISOBUTYRYL FEN TANYL (N–(2 16
–FLUOROPHENYL )–N–(1–PHENETHYLPIPERIDIN –4–YL)ISOBUTYRAMIDE ); 17
(65) ORTHO–METHYL ACETYLFENTANY L (N–(2–METHYLPHENYL )–N–18
(1–PHENETHYLPIPERIDIN –4–YL)ACETAMIDE; ALSO KNOWN AS 2–METHYL 19
ACETYLFENTANYL ); 20
(66) ORTHO–METHYL METHOXYACETYL FENTANYL (2–METHOXY–N 21
–(2–METHYLPHENYL )–N–(1–PHENETHYLPIPERIDIN –4–YL)ACETAMIDE; ALSO 22
KNOWN AS 2–METHYL METHOXYACETYL FENTANYL); 23
(67) PARA–CHLOROISOBUTYRYL FEN TANYL (N–(4–CHLOROPHENYL ) 24
–N–(1–PHENETHYLPIPERIDIN –4–YL)ISOBUTYRAMIDE); 25
(68) PARA–FLUOROBUTYRYL FENTAN YL (N–(4–FLUOROPHENYL )–N 26
–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ); 27
[(51)] (69) para–fluorofentanyl (N–(4–fluorophenyl)–N–[1–(2–phenethyl) 28
–4– piperidinyl] propanamide; 29 6 SENATE BILL 189
(70) PARA–FLUORO FURANYL FENTA NYL (N–(4–FLUOROPHENYL )–N–1
(1–PHENETHYLPIPERIDIN –4–YL)FURAN–2–CARBOXAMIDE ); 2
(71) PARA–METHOXYBUTYRYL FENTA NYL (N–(4–METHOXYPHENYL ) 3
–N–(1–PHENETHYLPIPERIDIN –4–YL)BUTYRAMIDE ); 4
(72) PARA–METHYLFENTANYL (N–(4–METHYLPHENYL )–N 5
–(1–PHENETHYLPIPERIDIN –4–YL)PROPIONAMIDE; ALSO KNOWN AS 4– 6
METHYLFENTANYL ); 7
[(52)] (73) PEPAP (1–(–2–phenethyl)–4–phenyl–4–acetoxypiperidine); 8
[(53)] (74) phenadoxone; 9
[(54)] (75) phenampromide; 10
[(55)] (76) phenomorphan; 11
[(56)] (77) phenoperidine; 12
(78) PHENYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 13
–N–PHENYLBENZAMIDE ; ALSO KNOWN AS BENZOY L FENTANYL); 14
[(57)] (79) piritramide; 15
[(58)] (80) proheptazine; 16
[(59)] (81) properidine; 17
[(60)] (82) propiram; 18
[(61)] (83) racemoramide; 19
[(62)] (84) tetrahydrofuranyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N 20
– phenyltetrahydrofuran–2–carboxamide); 21
[(63)] (85) thiofentanyl (N–PHENYL–N–[1–(2 22
–THIENYL)ETHYL–4–PIPERIDINYL]PROPANAMIDE ); 23
(86) THIOFURANYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 24
–N–PHENYLTHIOPHENE –2–CARBOXAMIDE ; ALSO KNOWN AS 2–THIOFURANYL 25
FENTANYL; THIOPHENE FENTANYL ); 26
[(64)] (87) tilidine; 27 SENATE BILL 189 7
[(65)] (88) trimeperidine; [and] 1
[(66)] (89) U–47700 (3,4–dichloro–N–[2–(dimethylamino)cyclohexyl]–N 2
– methylbenzamide); AND 3
(90) VALERYL FENTANYL (N–(1–PHENETHYLPIPERIDIN –4–YL) 4
–N–PHENYLPENTANAMIDE ). 5
(c) Unless specifically excepted under this subtitle or listed in another schedule, 6
any of the following opium derivatives, including their salts, isomers, and salts of isomers, 7
whenever the existence of such salts, isomers, or salts of isomers is possible within the 8
specific chemical designation, are substances listed in Schedule I: 9
(1) acetorphine; 10
(2) acetyldihydrocodeine; 11
(3) benzylmorphine; 12
(4) codeine methylbromide; 13
(5) codeine–N–oxide; 14
(6) cyprenorphine; 15
(7) desomorphine; 16
(8) dihydromorphine; 17
(9) drotebanol; 18
(10) etorphine (except hydrochloride salt); 19
(11) heroin; 20
(12) hydromorphinol; 21
(13) methyldesorphine; 22
(14) methyldihydromorphine; 23
(15) morphine methylbromide; 24
(16) morphine methylsulfonate; 25
(17) morphine–N–oxide; 26 8 SENATE BILL 189
(18) myrophine; 1
(19) nicocodeine; 2
(20) nicomorphine; 3
(21) normorphine; 4
(22) pholcodine; and 5
(23) thebacon. 6
(d) Unless specifically excepted under this subtitle or listed in another schedule, 7
any material, compound, mixture, or preparation that contains any quantity of the 8
following hallucinogenic substances, or that contains any of its salts, isomers, including 9
optical, position, and geometric isomers, or salts of isomers, whenever the existence of such 10
salts, isomers, or salts of isomers is possible within the specific chemical designation, is a 11
substance listed in Schedule I: 12
(1) alpha–ethyltryptamine; 13
(2) 4–bromo–2,5–dimethoxy–amphetamine; 14
(3) 4–bromo–2,5–dimethoxyphenethylamine; 15
(4) 2,5–dimethoxyamphetamine; 16
(5) 2,5–dimethoxy–4–ethylamphetamine (DOET); 17
(6) 2,5–dimethoxy–4–(n)–propylthiophenethylamine (2C–T–7); 18
(7) 4–methoxyamphetamine (PMA); 19
(8) 5–methoxy–3,4–methylenedioxy–amphetamine; 20
(9) 4–methyl–2,5–dimethoxy–amphetamine; 21
(10) 3,4–methylenedioxy amphetamine; 22
(11) 3,4–methylenedioxymethamphetamine (MDMA); 23
(12) 3,4–methylenedioxy–N–ethylamphetamine (MDA); 24
(13) N–hydroxy–3,4–methylenedioxyamphetamine; 25
(14) 3,4,5–trimethoxyamphetamine; 26 SENATE BILL 189 9
(15) 5–methoxy–N, N–dimethyltryptamine; 1
(16) alpha–methyltryptamine (AMT); 2
(17) bufotenine; 3
(18) diethyltryptamine (DET); 4
(19) dimethyltryptamine (DMT); 5
(20) 5–methoxy–N, N–diisopropyltryptamine (5–MeO–DIPT); 6
(21) ibogaine; 7
(22) lysergic acid diethylamide; 8
(23) marijuana; 9
(24) mescaline; 10
(25) parahexyl–7374; 11
(26) peyote (meaning all parts of the plant presently classified botanically 12
as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract 13
from any part of such plant, and every compound, manufacture, salt, derivative, mixture, 14
or preparation of such plant, its seeds, or extracts); 15
(27) N–ethyl–3–piperidyl benzilate; 16
(28) N–methyl–3–piperidyl benzilate; 17
(29) psilocybin; 18
(30) psilocyn; 19
(31) tetrahydrocannabinols; 20
(32) ethylamine analog of phencyclidine (N –ethyl–1 21
–phenylcyclohexylamine); 22
(33) pyrrolidine analog of phencyclidine (1 –(1–phenylcyclohexyl) 23
– pyrrolidine); 24
(34) thiophene analog of phencyclidine (1 –[1–(2–thienyl)–cyclohexyl] 25
– piperidine); 26
10 SENATE BILL 189
(35) 1–[1–(2–thienyl)cyclohexyl]pyrrolidine; 1
(36) 4–methylmethcathinone (mephedrone); 2
(37) 3, 4–methylenedioxypyrovalerone (MDPV); 3
(38) 2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2C–E); 4
(39) 2–(2,5–dimethoxy–4–methylphenyl) ethanamine (2C–D); 5
(40) 2–(4–chloro–2,5–dimethoxyphenyl) ethanamine (2C–C); 6
(41) 2–(4–iodo–2,5–dimethoxyphenyl) ethanamine (2C–I); 7
(42) 2–[4–(ethylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–2); 8
(43) 2–[4–(isopropylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–4); 9
(44) 2–(2,5–dimethoxyphenyl) ethanamine (2C–H); 10
(45) 2–(2,5–dimethoxy–4–nitro–phenyl) ethanamine (2C–N); 11
(46) 2–(2,5–dimethoxy–4–(n)–propylphenyl) ethanamine (2C–P); 12
(47) 3,4–methylenedioxy–N–methylcathinone (methylone); 13
(48) (1–pentyl–1H–indol–3–yl) (2,2,3,3–tetramethylcyclopropyl) methanone 14
(UR–144); 15
(49) [1–(5–fluoro–pentyl)–1H–indol–3–yl](2,2,3,3–tetramethylcyclopropyl) 16
methanone (5–fluoro–UR–144, XLR11); 17
(50) N–(1–adamantyl)–1–pentyl–1H–indazole–3–carboxamide (APINACA, 18
AKB48); 19
(51) quinolin–8–yl 1–pentyl–1H–indole–3–carboxylate (PB–22); 20
(52) quinolin–8–yl 1–(5–fluoropentyl)–1H–indole–3–carboxylate (5–fluoro 21
– PB–22); 22
(53) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(4–fluorobenzyl)–1H– 23
indazole–3–carboxamide (AB–FUBINACA); 24
(54) N–(1–amino–3, 3 –dimethyl–1–oxobutan–2–yl)–1–pentyl–1H 25
–indazole–3–carboxamide (ADB–PINACA); 26
(55) 2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 27 SENATE BILL 189 11
(25I–NBOMe); 1
(56) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 2
(25C–NBOMe); 3
(57) 2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 4
(25B–NBOMe); 5
(58) marijuana extract (meaning an extract containing one or more 6
cannabinoids that has been derived from any plant of the genus cannabis, other than the 7
separated resin, whether crude or purified, obtained from the plant); 8
(59) 4–methyl–N–ethylcathinone (4–MEC); 9
(60) 4–methyl–alpha–pyrrolidinopropiophenone (4–MePPP); 10
(61) alpha–pyrrolidinopentiophenone (alpha–PVP); 11
(62) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) butan–1–one (butylone); 12
(63) 2–(methylamino)–1–phenylpentan–1–one (pentedrone); 13
(64) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) pentan–1–one (pentylone); 14
(65) 4–fluoro–N–methylcathinone (flephedrone); 15
(66) 3–fluoro–N–methylcathinone (3–FMC); 16
(67) 1–(naphthalen–2–yl)–2–(pyrrolidin–1–yl)pentan–1–one (naphyrone); 17
(68) alpha–pyrrolidinobutiophenone (alpha–PBP); 18
(69) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–1H– 19
indazole–3–carboxamide (AB–CHMINACA); 20
(70) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–pentyl–1H–indazole–3– 21
carboxamide (AB–PINACA); 22
(71) [1–(5–fluoropentyl)–1H–indazol–3–yl](naphthalen–1–yl)methanone 23
(THJ–2201); [and] 24
(72) N–(1–amino–3,3–dimethyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–25
1H–indazole–3–carboxamide (MAB–CHMINACA); 26
(73) METHYL 2–(1–(5–FLUOROPENTYL )–1H–NDAZOLE–3 27
–CARBOXAMID O)–3,3–DIMETHYLBUTANOATE (OTHER NAMES : 5F–ADB; 5F–28
MDMB–PINACA); 29 12 SENATE BILL 189
(74) METHYL 2–(1–(5–FLUOROPENTYL )–1H–INDAZOLE–3 1
–CARBOXAMIDO )–3–METHYLBUTANOATE (OTHER NAMES : 5F–AMB); 2
(75) N–(ADAMANTAN –1–YL)–1–(5–FLUOROPENTYL )–1H–INDAZOLE– 3
3–CARBOXAMIDE (OTHER NAMES: 5F–APINACA, 5F–AKB48); 4
(76) N–(1–AMINO–3,3–DIMETHYL–1–OXOBUTAN–2–YL)–1–(4–5
FLUOROBENZYL )–1H–INDAZOLE–3–CARBOXAMIDE (OTHER NAMES : ADB–6
FUBINACA); 7
(77) METHYL 2–(1–(CYCLOHEXYLMETHYL )–1H–INDOLE–3 8
–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (OTHER NAMES : MDMBA–CHMICA, 9
MMB–CHMINACA); 10
(78) METHYL 2–(1–(4–FLUOROBENZYL )–1H–INDAZOLE–3 11
–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (OTHER NAMES : MDMB–12
FUBINACA); 13
(79) METHYL 2–(1–(4–FLUOROBENZYL )–1H–INDAZOLE–3 14
–CARBOXAMIDO )–3–METHYLBUTANOATE , (FUB–AMB, MMB–FUBINACA, AMB–15
FUBINACA); 16
(80) 1–(1,3–BENZODIOXOL –5–YL)–2–(ETHYLAMINO )PROPAN–1–ONE 17
(ETHYLONE); 18
(81) NAPHTHALEN –1–YL 1–(5–FLUOROPENTYL )–1H–INDOLE–3–19
CARBOXYLATE (OTHER NAMES : NM2201; CBL2201); 20
(82) N–(1–AMINO–3–METHYL–1–OXOBUTAN–2–YL)–1–(5–21
FLUOROPENTYL )–1H–INDAZOLE–3–CARBOXAMIDE (OTHER NAME : 5F–AB–22
PINACA); 23
(83) 1–(4–CYANOBUTYL )–N–(2–PHENYLPROPAN –2–YL)–1H–24
INDAZOLE–3–CARBOXAMIDE (OTHER NAMES : 4–CN–CUMYL–BUTINACA; 4 25
–CYANO–CUMYL–BUTINACA; 4–CN–CUMYL BINACA; CUMYL–4–CN–26
BINACA; SGT–78); 27
(84) METHYL 2–(1–(CYCLOHEXYLMETHYL )–1H–INDOLE–3 28
–CARBOXAMIDO )–3–METHYLBUTANOATE (OTHER NAMES : MMB–CHMICA; AMB–29
CHMICA); 30
(85) 1–(5–FLUOROPENTYL )–N–(2–PHENYLPROPAN –2–YL)–1H–31
PYRROLO[2,3B]PYRIDINE–3–CARBOXAMIDE (OTHER NAME : 5F–CUMYL–32 SENATE BILL 189 13
P7AICA); 1
(86) N–ETHYLPENTYLONE (OTHER NAMES: EPHYLONE, 1–(1,3–2
BENZODIOXOL –5–YL)–2–(ETHYLAMINO )PENTAN–1–ONE); 3
(87) METHYL 2–(1–(4–FLUOROBUTYL )–1H–INDAZOLE–3 4
–CARBOXAMIDO )–3,3–DIMETHYLBUTANOATE (4F–MDMB–BINACA, 4F–MDMB–5
BUTINACA); AND 6
(88) 1–(4–METHOXYPHENYL )–N–METHYLPROPAN –2–AMINE (OTHER 7
NAMES: PARA–METHOXYMETHAMPHETAMI NE, PMMA). 8
(e) Unless specifically excepted under this subtitle or listed in another schedule, 9
a material, compound, mixture, or preparation that contains any quantity of the following 10
substances having depressant effects on the central nervous system, or that contains its 11
salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of 12
isomers is possible within the specific chemical designation, is a substance listed in 13
Schedule I: 14
(1) gamma–hydroxybutyric acid (GHB); 15
(2) mecloqualone; and 16
(3) methaqualone. 17
(f) Unless specifically excepted or listed in another schedule, any material, 18
compound, mixture, or preparation that contains any quantity of the following substances 19
having a stimulant effect on the central nervous system, or that contains its salts, isomers, 20
or salts of isomers, is a substance listed in Schedule I: 21
(1) aminorex; 22
(2) N–benzylpiperazine (BZP); 23
(3) cathinone; 24
(4) fenethylline; 25
(5) methcathinone; 26
(6) [(+)cis–4–methylaminorex ((+)cis–4,5–dihydro–4–methyl–5–phenyl–2 27
– oxazolamine)] (±)CIS–4–METHYLAMINOREX ((±)CIS–4,5–DIHYDRO–4–METHYL–5– 28
PHENYL–2–OXAZOLAMINE ); 29
(7) N–ethylamphetamine; and 30
14 SENATE BILL 189
(8) N, N–dimethylamphetamine. 1
(g) Unless specifically excepted under this subtitle or listed in another schedule, 2
any material, compound, mixture, or preparation that contains any quantity of the 3
following substances, or that contains their salts, isomers, or salts of isomers, whenever the 4
existence of such salts, isomers, or salts of isomers is possible within the specific chemical 5
designation, is a substance listed in Schedule I: 6
(1) 5–(1, 1–dimethylheptyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol 7
(CP– 47,497); 8
(2) 5–(1,1–dimethyloctyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP 9
– 47,497 C8 homolog); 10
(3) 1–pentyl–3–(1–naphthoyl) indole (JWH–018 and AM678); 11
(4) 1–butyl–3–(1–naphthoyl) indole (JWH–073); 12
(5) 1–hexyl–3–(1–naphthoyl) indole (JWH–019); 13
(6) 1–[2–(4–morpholinyl)ethyl]–3–(1–naphthoyl) indole (JWH–200); 14
(7) 1–pentyl–3–(2–methoxyphenylacetyl) indole (JWH–250); 15
(8) 1–pentyl–3–[1–(4–methoxynaphthoyl)] indole (JWH–081); 16
(9) 1–pentyl–3–(4–methyl–1–naphthoyl) indole (JWH–122); 17
(10) 1–pentyl–3–(4–chloro–1–naphthoyl) indole (JWH–398); 18
(11) 1–(5–fluoropentyl)–3–(1–naphthoyl) indole (AM2201); 19
(12) 1–(5–fluoropentyl)–3–(2–iodobenzoyl) indole (AM694); 20
(13) 1–pentyl–3–[(4–methoxy)–benzoyl] indole (SR–19 and RCS–4); 21
(14) 1–cyclohexylethyl–3–(2–methoxyphenylacetyl) indole 7008 (SR–18 and 22
RCS–8); and 23
(15) 1–pentyl–3–(2–chlorophenylacetyl) indole (JWH–203). 24
(h) (1) In this subsection: 25
(i) “controlled dangerous substance analogue” means a substance: 26
1. that has a chemical structure substantially similar to the 27
chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II; 28 SENATE BILL 189 15
and 1
2. that has a stimulant, depressant, or hallucinogenic effect 2
on the central nervous system that is substantially similar to or greater than the stimulant, 3
depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous 4
substance listed in Schedule I or Schedule II; but 5
(ii) “controlled dangerous substance analogue” does not include: 6
1. a controlled dangerous substance; 7
2. a substance for which there is an approved new drug 8
application; or 9
3. a substance exempted for investigational use under § 506 10
of the Federal Food, Drug, and Cosmetic Act. 11
(2) To the extent intended for human consumption, each controlled 12
dangerous substance analogue is a substance listed in Schedule I. 13
(i) The Department may not add a substance to Schedule I under § 5–202 of this 14
title unless the Department finds: 15
(1) a high potential for abuse of the substance; 16
(2) no accepted medical use in the United States for the substance; and 17
(3) a lack of accepted safety for use of the substance under medical 18
supervision. 19
5–403. 20
(a) Schedule II consists of each controlled dangerous substance: 21
(1) listed in this section; 22
(2) added to Schedule II by the Department under § 5–202(b) of this title; 23
or 24
(3) designated as a Schedule II controlled dangerous substance by the 25
federal government unless the Department objects under § 5–202(f) of this title. 26
(b) Unless specifically excepted or unless listed in another schedule, any of the 27
following substances whether produced directly or indirectly by extraction from substances 28
of vegetable origin, or independently by means of chemical synthesis, or by a combination 29
of extraction and chemical synthesis: 30
16 SENATE BILL 189
(1) opium and opiate, and any salt, compound, derivative, or preparation 1
of opium or opiate excluding apomorphine, thebaine–derived butorphanol, dextrorphan, 2
nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their 3
respective salts, but including the following: 4
(i) codeine; 5
(ii) dihydroetorphine; 6
(iii) ethylmorphine; 7
(iv) etorphine hydrochloride; 8
(v) granulated opium; 9
(vi) hydrocodone; 10
(vii) hydromorphone; 11
(viii) metopon; 12
(ix) morphine; 13
(x) NOROXYMORPHONE ; 14
(XI) opium extracts; 15
[(xi)] (XII) opium fluid; 16
[(xii)] (XIII) oripavine; 17
[(xiii)] (XIV) oxycodone; 18
[(xiv)] (XV) oxymorphone; 19
[(xv)] (XVI) powdered opium; 20
[(xvi)] (XVII) raw opium; 21
[(xvii)] (XVIII) thebaine; and 22
[(xviii)] (XIX) tincture of opium; 23
(2) any salt, compound, derivative, or preparation thereof which is 24
chemically equivalent or identical with any of the substances referred to in item (1) of this 25 SENATE BILL 189 17
subsection, except that these substances may not include the isoquinoline alkaloids of 1
opium; 2
(3) opium poppy and poppy straw; 3
(4) coca leaves and any salt, compound, derivative, or preparation of coca 4
leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of 5
isomers and derivatives, and any salt, compound, derivative, or preparation thereof which 6
is chemically equivalent or identical with any of these substances, except that the 7
substances may not include: 8
(i) decocainized coca leaves or extraction of coca leaves, which 9
extractions do not contain cocaine or ecgonine; or 10
(ii) ioflupane; and 11
(5) concentrate of poppy straw (the crude extract of poppy straw in either 12
liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium 13
poppy). 14
(c) Unless specifically excepted or unless in another schedule any of the following 15
opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers 16
whenever the existence of such isomers, esters, ethers, and salts is possible within the 17
specific chemical designation, dextrorphan and levopropoxyphene excepted: 18
(1) alfentanil; 19
(2) alphaprodine; 20
(3) anileridine; 21
(4) bezitramide; 22
(5) bulk dextropropoxyphene (non–dosage forms); 23
(6) carfentanil; 24
(7) dihydrocodeine; 25
(8) diphenoxylate; 26
(9) fentanyl; 27
(10) isomethadone; 28
(11) levo–alphacetylmethadol; 29
18 SENATE BILL 189
(12) levomethorphan; 1
(13) levorphanol; 2
(14) metazocine; 3
(15) methadone; 4
(16) methadone – intermediate, 4–cyano–2–dimethylamino–4, 4–diphenyl 5
butane; 6
(17) moramide – intermediate, 2–methyl–3– morpholino–1, 1 7
– diphenylpropane–carboxylic acid; 8
(18) OLICERIDINE (N–[(3–METHOXYTHIOPHEN –2–YL)METHYL] 9
({2–[(9R)–9–(PYRIDIN–2–YL)–6–OXASPIRO [4.5]DECAN–9–YL]ETHYL})AMINE 10
FUMARATE); 11
(19) pethidine (meperidine); 12
[(19)] (20) pethidine – intermediate – A, 4–cyano–1–methyl–4 13
– phenylpiperidine; 14
[(20)] (21) pethidine – intermediate – B, ethyl–4–phenylpiperidine–4 15
– carboxylate; 16
[(21)] (22) pethidine – intermediate – C, 1–methyl–4–phenylpiperidine–4 17
– carboxylic acid; 18
[(22)] (23) phenazocine; 19
[(23)] (24) piminodine; 20
[(24)] (25) racemethorphan; 21
[(25)] (26) racemorphan; 22
[(26)] (27) remifentanil; 23
[(27)] (28) sulfentanil; 24
[(28)] (29) tapentadol; and 25
[(29)] (30) thiafentanil. 26
SENATE BILL 189 19
(d) Unless specifically excepted under this subtitle or listed in another schedule, 1
a substance is listed in Schedule II if the substance includes a material, compound, mixture, 2
or preparation that contains any quantity of the following substances having a potential 3
for abuse associated with a stimulant effect on the central nervous system: 4
(1) amphetamine, its salts, optical isomers, and salts of its optical isomers; 5
(2) methamphetamine, its salts, isomer, and salts of isomers; 6
(3) phenmetrazine and its salts; 7
(4) methylphenidate; and 8
(5) lisdexamfetamine, its salts, isomers, and salts of isomers. 9
(e) Unless specifically excepted under this subtitle or listed in another schedule, 10
a substance is listed in Schedule II if the substance includes a material, compound, mixture, 11
or preparation that contains any quantity of the following substances having a depressant 12
effect on the central nervous system, including its salts, isomers, and salts of isomers 13
whenever the existence of such salts, isomers, and salts of isomers is possible within the 14
specific chemical designation: 15
(1) amobarbital; 16
(2) glutethimide; 17
(3) pentobarbital; 18
(4) phencyclidine; and 19
(5) secobarbital. 20
(f) [As] HALLUCINOGENIC SUBSTA NCES, AS listed in Schedule II under Title 21
21 of the Code of Federal Regulations. 22
(1) nabilone; and 23
(2) dronabinol [(–)–delta–9–trans tetrahydrocannabinol] in an oral 24
solution in a drug product approved for marketing by the United States Food and Drug 25
Administration. 26
(g) Unless specifically excepted or unless listed in another schedule, any material, 27
compound, mixture, or preparation which contains any quantity of the following 28
substances: 29
(1) immediate precursor to amphetamine and methamphetamine: 30
20 SENATE BILL 189
(i) phenylacetone; and 1
(ii) reserved; 2
(2) immediate precursors to phencyclidine (PCP): 3
(i) 1–phenylcyclohexylamine; and 4
(ii) 1–piperidinocyclohexanecarbonitrile (PCC); and 5
(3) immediate precursor to fentanyl: 6
(i) 4–anilino–N–phenethylpiperidine (ANPP); and 7
(ii) [reserved] N–PHENYL–N–(PIPERIDIN–4–YL)PROPIONAMIDE 8
(NORFENTANYL ). 9
(h) The Department may not add a substance to Schedule II under § 5–202 of this 10
title unless the Department finds: 11
(1) a high potential for abuse of the substance; 12
(2) currently accepted medical use of the substance in the United States, 13
or currently accepted medical use with severe restrictions; and 14
(3) evidence that abuse of the substance may lead to severe psychological 15
or physical dependence. 16
5–404. 17
(a) Schedule III consists of each controlled dangerous substance by whatever 18
official name, common or usual name, chemical name, or brand name designated: 19
(1) listed in this section; 20
(2) added to Schedule III by the Department under § 5–202(b) of this title; 21
or 22
(3) designated as a Schedule III controlled dangerous substance by the 23
federal government unless the Department objects under § 5–202(f) of this title. 24
(b) (1) Unless specifically excepted or listed in another schedule, a substance 25
is listed in Schedule III if the substance includes a material, compound, mixture, or 26
preparation that contains any quantity of the following substances having a stimulant 27
effect on the central nervous system: 28
(i) those compounds, mixtures, or preparations in dosage unit form 29 SENATE BILL 189 21
containing any stimulant substances listed in Schedule II, which compounds, mixtures, or 1
preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the 2
Code of Federal Regulations, and any other drug of the quantitative composition shown in 3
that list for those drugs or that is the same except that it contains a lesser quantity of 4
controlled substances; 5
(ii) benzphetamine; 6
(iii) chlorphentermine; 7
(iv) clortermine; and 8
(v) phendimetrazine. 9
(2) Subject to paragraph (3) of this subsection, substances in Schedule III 10
include: 11
(i) a salt of a substance listed in this subsection; 12
(ii) an optical, position, or geometric isomer of a substance listed in 13
this subsection; or 14
(iii) a salt of an isomer of a substance listed in this subsection. 15
(3) Unless listed in another schedule, a salt, isomer, or salt of an isomer 16
described in paragraph (2) of this subsection may be included in Schedule III only if the 17
existence of the salts, isomers, and salts of isomers is possible within the specific chemical 18
designation. 19
(c) Unless listed in another schedule, a substance is listed in Schedule III if the 20
substance includes a material, compound, mixture, or preparation that contains any 21
quantity of the following substances having a potential for abuse associated with a 22
depressant effect on the central nervous system: 23
(1) any compound, mixture, or preparation containing: 24
(i) amobarbital; 25
(ii) secobarbital; 26
(iii) pentobarbital; or 27
(iv) any salt thereof and one or more other active medicinal 28
ingredients that are not listed in any schedule; 29
(2) any suppository dosage form containing: 30
22 SENATE BILL 189
(i) amobarbital; 1
(ii) secobarbital; 2
(iii) pentobarbital; or 3
(iv) any salt of any of these drugs and approved by the U.S. Food and 4
Drug Administration for marketing only as a suppository; 5
(3) except those substances that are specifically listed in other schedules, 6
a substance that contains any quantity of a derivative of barbituric acid, a salt of a 7
derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic 8
ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal); 9
(4) chlorhexadol; 10
(5) embutramide; 11
(6) any drug product containing gamma hydroxybutyric acid, including its 12
salts, isomers, and salts of isomers, for which an application is approved under Section 505 13
of the Federal Food, Drug, and Cosmetic Act; 14
(7) ketamine, its salts, isomers, and salts of isomers; 15
(8) lysergic acid; 16
(9) lysergic acid amide; 17
(10) methyprylon; 18
(11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA); 19
(12) sulfondiethylmethane; 20
(13) sulfonethylmethane; 21
(14) sulfonmethane; and 22
(15) tiletamine and zolazepam or any salt thereof, including a 23
tiletamine–zolazepam combination product (trade name Telazol). 24
(d) As listed in Schedule III under Title 21 of the Code of Federal Regulations, 25
nalorphine 9400. 26
(e) Unless specifically excepted or unless listed in another schedule: 27
(1) substances listed in Schedule III include any material, compound, 28 SENATE BILL 189 23
mixture, or preparation containing any of the following narcotic drugs, or their salts 1
calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: 2
(i) not more than 1.80 grams of codeine per 100 milliliters or not 3
more than 90 milligrams per dosage unit, with an equal or greater quantity of an 4
isoquinoline alkaloid of opium; 5
(ii) not more than 1.80 grams of codeine per 100 milliliters or not 6
more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients 7
in recognized therapeutic amounts; 8
(iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters 9
or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic 10
ingredients in recognized therapeutic amounts; 11
(iv) not more than 300 milligrams of ethylmorphine per 100 12
milliliters or not more than 15 milligrams per dosage unit, with one or more active, 13
nonnarcotic ingredients in recognized therapeutic amounts; 14
(v) not more than 500 milligrams of opium per 100 milliliters or per 15
100 grams, or not more than 25 milligrams per dosage unit, with one or more active, 16
nonnarcotic ingredients in recognized therapeutic amounts; 17
(vi) not more than 100 milligrams of opium per 100 milliliters or per 18
100 grams, or not more than 5 milligrams per dosage unit; and 19
(vii) not more than 50 milligrams of morphine per 100 milliliters or 20
per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic 21
amounts. 22
(2) any material, compound, mixture, or preparation containing any of the 23
following narcotic drugs or their salts, as set forth below: 24
(i) buprenorphine; and 25
(ii) reserved. 26
(3) if not combined with one or more active medicinal ingredients that are 27
listed in another schedule, substances listed in Schedule III include a suppository dosage 28
form or salt of a suppository dosage that contains: 29
(i) amobarbital; 30
(ii) secobarbital; or 31
(iii) pentobarbital. 32
24 SENATE BILL 189
(f) (1) Except as provided in paragraph (2) of this subsection, an anabolic 1
steroid consisting of any material, compound, mixture, or preparation containing any 2
quantity of the following substances, including its salts, esters, and ethers: 3
(i) 3beta,17–dihydroxy–5a–androstane; 4
(ii) 3alpha,17beta–dihydroxy–5a–androstane; 5
(iii) 5 alpha–androstan–3,17–dione; 6
(iv) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1 7
–ene); 8
(v) 1–androstenediol (3alpha,17beta–dihydroxy–5alpha–androst 9
–1–ene); 10
(vi) 4–androstenediol (3beta,17beta–dihydroxy–androst–4–ene); 11
(vii) 5–androstenediol (3beta,17beta–dihydroxy–androst–5–ene); 12
(viii) 1–androstenedione; 13
(ix) 4–androstenedione; 14
(x) 5–androstenedione; 15
(xi) bolasterone; 16
(xii) boldenone; 17
(xiii) boldione; 18
(xiv) calusterone; 19
(xv) chlorotestosterone (clostebol); 20
(xvi) dehydrochloromethyltestosterone; 21
(xvii) desoxymethyltestosterone; 22
(xviii) delta1–dihydrotestosterone (17beta–hydroxy–5alpha–androst 23
–1–en–3–one); 24
(xix) dihydrotestosterone (4–dihydrotestosterone) (17beta–hydroxy 25
– androstan–3–one) (stanolone); 26
(xx) drostanolone; 27 SENATE BILL 189 25
(xxi) ethylestrenol; 1
(xxii) fluoxymesterone; 2
(xxiii) formebolone; 3
(xxiv) furazabol; 4
(xxv) 13beta–ethyl–17beta–hydroxygon–4–en–3–one; 5
(xxvi) 4–hydroxytestosterone; 6
(xxvii) 4–hydroxy–19–nortestosterone; 7
(xxviii) mestanolone (17alpha –methyl–17beta–hydroxy–5 8
–androstan–3–one); 9
(xxix) mesterolone; 10
(xxx) methandienone (methandrostenolone) (17alpha –methyl 11
–17beta–hydroxyandrost–1,4–dien–3–one); 12
(xxxi) methandriol; 13
(xxxii) methasterone; 14
(xxxiii) methenolone; 15
(xxxiv) 17alpha–methyl–3beta, 17beta –dihydroxy–5a 16
–androstane; 17
(xxxv) 17alpha–methyl–3alpha, 17beta–dihydroxy–5a–androstane; 18
(xxxvi) 17alpha–methyl–3beta, 17beta–dihydroxyandrost–4–ene; 19
(xxxvii) 17alpha–methyl–4–hydroxynandrolone; 20
(xxxviii) methyldienolone; 21
(xxxix) methyltrienolone; 22
(xl) methyltestosterone; 23
(xli) mibolerone; 24
(xlii) 17alpha–methyl–delta1–dihydrotestosterone; 25 26 SENATE BILL 189
(xliii) nandrolone; 1
(xliv) 19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene); 2
(xlv) 19–nor–4–androstenediol (3alpha, 17beta–dihydroxyestr–4 3
–ene); 4
(xlvi) 19–nor–5–androstenediol (3beta, 17beta–dihydroxyestr–5–ene); 5
(xlvii) 19–nor–5–androstenediol (3alpha, 17beta–dihydroxyestr–5 6
–ene); 7
(xlviii) 19–nor–4,9(10)–androstadienedione; 8
(xlix) 19–nor–4–androstenedione; 9
(l) 19–nor–5–androstenedione; 10
(li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4 11
–en–3–one); 12
(lii) norclostebol; 13
(liii) norethandrolone; 14
(liv) normethandrolone; 15
(lv) oxandrolone; 16
(lvi) oxymesterone; 17
(lvii) oxymetholone; 18
(lviii) prostanozol; 19
(lix) stanozolol; 20
(lx) stenbolone; 21
(lxi) testolactone; 22
(lxii) testosterone; 23
(lxiii) tetrahydrogestrinone; and 24
(lxiv) trenbolone. 25 SENATE BILL 189 27
(2) The following substances are not included in Schedule III: 1
(i) an estrogen, progestin, [or] corticosteroid, OR 2
DEHYDROEPIANDROSTERO NE; or 3
(ii) a substance covered by paragraph (1) of this subsection if: 4
1. expressly intended for administration through implants to 5
cattle or other nonhuman species; and 6
2. approved for that use by the U.S. Food and Drug 7
Administration. 8
(g) Hallucinogenic substances include: 9
(1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin 10
capsule in a U.S. Food and Drug Administration–approved product; and 11
(2) reserved. 12
(h) The Department may not add a substance to Schedule III under § 5–202 of 13
this title unless the Department finds: 14
(1) a potential for abuse of the substance that is less than that for the 15
substances listed in Schedule I and Schedule II; 16
(2) well documented and approved medical use of the substance in the 17
United States; and 18
(3) evidence that abuse of the substance may lead to moderate or low 19
physical dependence or high psychological dependence. 20
5–405. 21
(a) Schedule IV consists of each controlled dangerous substance: 22
(1) listed in this section; 23
(2) added to Schedule IV by the Department under § 5–202(b) of this title; 24
or 25
(3) designated as a Schedule IV controlled dangerous substance by the 26
federal government unless the Department objects under § 5–202(f) of this title. 27
(b) Unless specifically excepted or unless listed in another schedule, any material, 28
compound, mixture, or preparation containing any of the following narcotic drugs, or their 29 28 SENATE BILL 189
salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth 1
below: 2
(1) not more than 1 milligram of difenoxin and not less than 25 micrograms 3
of atropine sulfate per dosage unit; 4
(2) dextropropoxyphene (alpha–(+)–4–dimethylamino–1, 2–diphenyl–3 5
– methyl–2–propionoxybutane); and 6
(3) 2–[(dimethylamino)methyl]–1–(3–methoxyphenyl)cyclohexanol, its 7
salts, optical and geometric isomers and salts of these isomers (including tramadol). 8
(c) Substances listed in Schedule IV include a material, compound, mixture, or 9
preparation that contains any quantity of the following substances having a potential for 10
abuse associated with a depressant effect on the central nervous system, including its salts, 11
isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of 12
isomers is possible within the specific chemical designations: 13
(1) alfaxalone; 14
(2) alprazolam; 15
(3) barbital; 16
(4) brexanolone; 17
(5) bromazepam; 18
(6) camazepam; 19
(7) carisoprodol; 20
(8) chloral betaine; 21
(9) chloral hydrate; 22
(10) chlordiazepoxide; 23
(11) clobazam; 24
(12) clonazepam; 25
(13) clorazepate; 26
(14) clotiazepam; 27
(15) cloxazolam; 28 SENATE BILL 189 29
(16) delorazepam; 1
(17) diazepam; 2
(18) dichloralphenazone; 3
(19) estazolam; 4
(20) ethchlorvynol; 5
(21) ethinamate; 6
(22) ethyl loflazepate; 7
(23) fludiazepam; 8
(24) flunitrazepam; 9
(25) flurazepam; 10
(26) fospropofol; 11
(27) halazepam; 12
(28) haloxazolam; 13
(29) ketazolam; 14
(30) LEMBOREXANT ; 15
(31) loprazolam; 16
[(31)] (32) lorazepam; 17
[(32)] (33) lormetazepam; 18
[(33)] (34) mebutamate; 19
[(34)] (35) medazepam; 20
[(35)] (36) meprobamate; 21
[(36)] (37) methohexital; 22
[(37)] (38) methylphenobarbital (mephobarbital); 23 30 SENATE BILL 189
[(38)] (39) midazolam; 1
[(39)] (40) nimetazepam; 2
[(40)] (41) nitrazepam; 3
[(41)] (42) nordiazepam; 4
[(42)] (43) oxazepam; 5
[(43)] (44) oxazolam; 6
[(44)] (45) paraldehyde; 7
[(45)] (46) petrichloral; 8
[(46)] (47) phenobarbital; 9
[(47)] (48) pinazepam; 10
[(48)] (49) prazepam; 11
[(49)] (50) quazepam; 12
(51) REMIMAZOLAM ; 13
[(50)] (52) suvorexant (Belsomra); 14
[(51)] (53) temazepam; 15
[(52)] (54) tetrazepam; 16
[(53)] (55) triazolam; 17
[(54)] (56) zaleplon (Sonata); 18
[(55)] (57) zolpidem (Ambien); and 19
[(56)] (58) zopiclone (Lunesta). 20
(d) Substances listed in Schedule IV include: 21
(1) a material, compound, mixture, or preparation that contains 22
fenfluramine; and 23 SENATE BILL 189 31
(2) if its existence is possible: 1
(i) a salt of fenfluramine; 2
(ii) an optical, position, or geometric isomer of fenfluramine, 3
including dexfenfluramine; and 4
(iii) a salt of an isomer of fenfluramine. 5
(e) Substances listed in Schedule IV include: 6
(1) a material, compound, mixture, or preparation that contains lorcaserin; 7
and 8
(2) if its existence is possible: 9
(i) a salt of lorcaserin; 10
(ii) an optical, position, or geometric isomer of lorcaserin; and 11
(iii) a salt of an isomer of lorcaserin. 12
(f) Substances listed in Schedule IV include a material, compound, mixture, or 13
preparation that contains any quantity of the following substances having a potential for 14
abuse associated with a stimulant effect on the central nervous system, including its salts, 15
isomers, and salts of isomers: 16
(1) cathine ((+)–norpseudoephedrine); 17
(2) diethylpropion; 18
(3) fencamfamin; 19
(4) fenproporex; 20
(5) mazindol; 21
(6) mefenorex; 22
(7) modafinil; 23
(8) pemoline, including organometallic complexes and their chelates; 24
(9) phentermine; 25
(10) pipradrol; 26 32 SENATE BILL 189
(11) SERDEXMETHYLPHENIDAT E; 1
(12) sibutramine; 2
[(12)] (13) solriamfetol (2 –amino–3–phenylpropyl carbamate; 3
benzenepropanol, beta–amino–, carbamate (ester)); and 4
[(13)] (14) SPA ((–)–1–dimethylamino–1,2–diphenylethane). 5
(g) Unless specifically excepted or unless listed in another schedule, any material, 6
compound, mixture, or preparation that contains any quantity of the following substances, 7
including its salts: 8
(1) pentazocine; 9
(2) butorphanol (including its optical isomers); and 10
(3) eluxadoline (5 –[[[(2S)–2–amino–3–[4–aminocarbonyl)–2, 11
6– dimethylphenyl]–1–oxopropyl][(1S)–1–(4–phenyl–1H–imidazol–2– 12
yl)ethyl]amino]methyl]–2–methoxybenzoic acid) (including its optical isomers) and its 13
salts, isomers, and salts of isomers. 14
(h) By regulation, the Department may exempt from this section a compound, 15
mixture, or preparation that contains a depressant substance listed in subsection (c) of this 16
section if: 17
(1) the compound, mixture, or preparation contains an active medicinal 18
ingredient that does not have a depressant effect on the central nervous system; and 19
(2) the admixtures are included in combinations, quantity, proportion, or 20
concentration that vitiate the potential for abuse of the substances that have a depressant 21
effect on the central nervous system. 22
(i) The Department may not add a substance to Schedule IV under § 5–202 of 23
this title unless the Department finds that: 24
(1) the substance has a low potential for abuse relative to the substances 25
listed in Schedule III; 26
(2) the substance has currently accepted medical use in treatment in the 27
United States; and 28
(3) abuse of the substance may lead to limited physical dependence or 29
psychological dependence relative to the substances in Schedule III. 30
5–406. 31 SENATE BILL 189 33
(a) Schedule V consists of each controlled dangerous substance: 1
(1) listed in this section; 2
(2) added to Schedule V by the Department under § 5–202(b) of this title; 3
or 4
(3) designated as a Schedule V controlled dangerous substance by the 5
federal government unless the Department objects under § 5–202(f) of this title. 6
(b) Unless specifically excepted or unless listed in another schedule, any material, 7
compound, mixture, or preparation containing any of the following narcotic drugs and their 8
salts, as set forth below: 9
(1) reserved; and 10
(2) reserved. 11
(c) Any compound, mixture, or preparation containing any of the following 12
narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited 13
quantities as set forth below, which shall include one or more nonnarcotic active medicinal 14
ingredients in sufficient proportion to confer upon the compound, mixture, or preparation 15
valuable medicinal qualities other than those possessed by narcotic drugs alone: 16
(1) not more than 200 milligrams of codeine per 100 milliliters or per 100 17
grams; 18
(2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or 19
per 100 grams; 20
(3) not more than 100 milligrams of ethylmorphine per 100 milliliters or 21
per 100 grams; 22
(4) not more than 2.5 milligrams of diphenoxylate and not less than 25 23
micrograms of atropine sulfate per dosage unit; or 24
(5) NOT MORE THAN 0.5 MILLIGRAM OF DIFENOX IN AND NOT LESS 25
THAN 25 MICROGRAMS OF ATROPI NE SULFATE PER DOSAG E UNIT (difenoxin 26
preparations 0.5mg/25ug ATSO4/DU (MOTOFEN) ). 27
(d) Unless specifically exempted or excluded or unless listed in another schedule, 28
any material, compound, mixture, or preparation that contains any quantity of the 29
following substances having a stimulant effect on the central nervous system, including its 30
salts, isomers, and salts of isomers: 31
(1) pyrovalerone; and 32 34 SENATE BILL 189
(2) reserved. 1
(e) Unless specifically exempted or excluded or unless listed in another schedule, 2
any material, compound, mixture, or preparation that contains any quantity of the 3
following substances having a depressant effect on the central nervous system, including 4
its salts: 5
(1) brivaracetam ((2S) –2–[(4R)–2–oxo–4–propylpyrrolidin–1–yl] 6
butanamide) (Briviact); 7
(2) CENOBAMATE ([(1R)–1–(2–CHLOROPHENYL )–2–(TETRAZOL–2 8
–YL)ETHYL] CARBAMATE ; 2H–TETRAZOLE–2–ETHANOL, ALPHA–(2 9
–CHLOROPHENYL )–, CARBAMATE (ESTER), (ALPHAR)–; CARBAMIC ACID (R)–(+)–1 10
–(2–CHLOROPHENYL )–2–(2H–TETRAZOL–2–YL)ETHYL ESTER); 11
(3) ezogabine [N–[2–amino–4–(4–fluorobenzylamino)–phenyl] 12
–carbamic acid ethyl ester] (Potiga); 13
[(3)] (4) lacosamide [(R) –2–acetoamido–N–benzyl–3–methoxy 14
–propionamide] (Vimpat); [and] 15
(5) LASMIDITAN [2,4,6–TRIFLUORO–N–(6–(1–METHYLPIPERIDINE 16
–4–CARBONYL)PYRIDINE–2–YL–BENZAMIDE]; AND 17
[(4)] (6) pregabalin [(S)–3–(aminomethyl)–5–methylhexanoic acid] 18
(Lyrica). 19
[(f) A drug product in finished dosage formulation that has been approved by the 20
United States Food and Drug Administration that contains cannabidiol (2–[1R–3–methyl 21
–6R–(1–methylethenyl)–2–cyclohexen–1–yl]–5–pentyl–1,3–benzenediol) derived from 22
cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.] 23
[(g)] (F) The Department may not add a substance to Schedule V under § 5–202 24
of this title unless the Department finds: 25
(1) the substance has a low potential for abuse relative to the substances 26
listed in Schedule IV; 27
(2) the substance has currently accepted medical use in the United States; 28
and 29
(3) abuse of the substance may lead to limited physical dependence or 30
psychological dependence liability relative to the substances listed in Schedule IV. 31
SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 32 SENATE BILL 189 35
October 1, 2022. 1